NCT05747521

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

A Single Arm, Single Center, Prospective Clinical Study of Anrotinib Hydrochloride Combined With Doxorubicin in the Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 85 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, single-arm, single-center, prospective clinical study with an estimated 58 patients enrolled to explore the efficacy and safety of anrotinib hydrochloride in combination with doxorubicin and radiotherapy in patients with high-grade soft tissue sarcoma.

Detailed description

This is a single-arm, single-center, prospective investigator-initiated clinical study of 58 patients enrolled in Henan Cancer Hospital to explore the efficacy and safety of anrotinib hydrochloride combined with doxorubicin and radiotherapy in patients with high-grade soft tissue sarcoma.

Conditions

• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	Anrotinib hydrochloride combined with adriamycin	To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma

Timeline

• Start date: 2021-04-29
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2023-02-28
• Last updated: 2023-02-28

Locations

1 site across 1 country: China